A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

Prior treatment

• Use of any prescription drug, herbal and compound decoction, vitamins, minerals, and OTC drugs and nutritional supplements that alter lipid metabolism within 14 days prior to Check-in and planned use of the above drugs throughout the study;
• Prior treatment with PCSK9 inhibitors, including mAbs, siRNA products, or any Adnectin products;
• Less than 30 days or less than 5 half-lives (drug) since the end of participation in another clinical trial (drug or device), whichever is longer;
• Use of any other biologics within 3 months prior to investigational product administration;

Other illness

• Positive blood screen for HIV antibody, Treponema pallidum antibody, HBsAg or HCV antibody;
• History of prescription drug abuse, illicit drug use or alcohol abuse;
• History of allergy to protein-based biologics including, but not limited to, mAbs and vaccine;
• Any other significant clinical diseases or psychological diseases that the investigator considers to be inappropriate for participation in this study.

Lab values

• Clinically significant liver function test abnormalities at screening, such as AST or ALT \> 2 × ULN, total bilirubin \> 1.5 × ULN, or ALP \> 2 × ULN based on normal values;
• CK \> 3 × ULN at the screening visit, it can be retested if considered to be related to exercise;

• Men and women who are ≥18 and ≤55 years of age with elevated LDL-C Levels;
• LDL-C ≥ 2.6 mmol/L (100 mg/dL) and ≤ 4.9 mmol/L (190 mg/dL) and TG ≤ 2.83 mmol/L (250 mg/dL) who are not on a lipid-lowering therapy 30 days prior to screening;
• Body mass index (BMI) ≥18 and≤28 kg/m2